Innovent Receives the NMPA’s Approval for Byvasda (biosimilar, bevacizumab) to Treat Non-Small Cell Lung Cancer and Metastatic Colorectal Cancer in China

Innovent and Eli Lilly Report Results of TYVYT (sintilimab) in P-II ORIENT-2 Study as 2L Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma

Shots:

  • The NMPA has approved Byvasda for the treatment of patients with NSCLC and metastatic colorectal cancer. The approval follows TYVYT (sintilimab injection) approval, indicated to treat patients with Hodgkin’s lymphoma, granted in Dec’2018
  • The launch of Byvasda will provide Chinese patients with high-quality and relatively more affordable bevacizumab biosimilar injection
  • In Jan’2020, Innovent granted commercial rights of Byvasda to in the US and Canada to Coherus BioSciences. Byvasda is a recombinant humanized anti-VEGF mAb targeting VEGF receptors on the surface of vascular endothelial cells, thus inhibiting signaling pathways such as PI3K-Akt/PKB and Ras-Raf-MEK-ERK

Click here to read full press release/ article | Ref: Buinesswire | Image: Innovent